Yoda Therapeutics Inc. (YODA), an AI-driven company that focuses on Central Nervous System (CNS) drugs, today announced the dosing of the first patient in the Phase 2 trial of YA-101 for Multiple ...

To accelerate potential completion of ongoing partnership restructuring negotiations, Orchestra BioMed and Terumo have elected to enter a mediation process and are currently working on a procedural ...

HistoIndex, a global leader in stain-free digital pathology solutions for managing fibrotic diseases, has announced the ...

stated Yufeng Jane Tseng, PhD, Chief Executive Officer of YODA ... accompanied by autonomic dysfunction. Patients experience debilitating symptoms, including severe orthostatic hypotension ...

Q4 2024 Earnings Call Transcript March 31, 2025 Cytosorbents Corporation beats earnings expectations. Reported EPS is $-0.03, ...

Executive dysfunction is a condition that affects ... You can do this. Be patient and remember –it's a process. Focus on ...

Blueprint Medicines' strong pipeline and Ayvakit growth make it promising. Read why BPMC stock is rated "Hold" due to high ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the company is scheduled to exhibit 4 abstracts at the ...

Recent research provides more support for the existence of long-term COVID and delves into potential causes and effects of ...

To their knowledge, their investigation is novel because it explored rates of formal evaluation and treatment for speech and swallowing dysfunction in patients who have myasthenia gravis.

Chief Executive Officer of Poxel. "With a significant number of type-2 diabetes patients also affected by renal impairment, the ability to offer a safe and effective treatment option is critical.